Docetaxel Injection, Solution
Product Images NDC 55150-380

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 55150-380). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (TAX316 Disease Free Survival K-M Curve)

A line graph displaying Disease-Free Survival (DFS) Probability (%) over time in months. Two curves are shown: one labeled 'TAC' represented by a solid line, and another labeled 'FAC' represented by a dotted line, illustrating comparative survival probabilities over approximately 70 months.*

FDA Label Image

Figure 10 –tax324 Overall Survival K-m Curve (Docetaxel Fig10)

A survival probability curve chart comparing TPF (n=255) and PF (n=246) treatments over a survival time of up to 72 months. The y-axis represents survival probability (%) and the x-axis represents survival time in months. A table below the graph shows the number of patients at risk at various time points for both treatment groups.*

FDA Label Image

Package Label-principal Display Panel-20 mg Per 2 mL (10 mg/ml) (Container Label)

Label for Docetaxel Injection, USP, showing a strength of 20 mg per 2 mL (10 mg/mL) in a 2 mL single-dose vial. The label indicates intravenous use only and cautions that it is a cytotoxic agent. Manufactured in India for AuroMedics Pharma LLC, E. Windsor, NJ. NDC 55150-378-01.*

FDA Label Image

Package Label-principal Display Panel-20 mg Per 2 mL (10 mg/ml) (Container-Carton (1 Vial))

The packaging label for Docetaxel Injection, USP, 20 mg per 2 mL (10 mg/mL) intravenous injection solution by Eugia US LLC. The label indicates it is an Rx only, single-dose 2 mL vial for infusion use, with warnings about concentration check and cytotoxicity. The label lists active ingredients and storage instructions, and includes distributor information for Auromedics Pharma LLC, made in India.*

FDA Label Image

Package Label-principal Display Panel-80 mg Per 8 mL (10 mg/ml) (Container Label)

Label for Docetaxel Injection, USP, 10 mg/mL concentration, with a total of 80 mg per 8 mL vial. The product is indicated for intravenous use and is labeled as a cytotoxic agent. It is a sterile, multiple-dose vial packaged by Eugia US LLC and manufactured by AuroMedics Pharma LLC in India. The label includes storage instructions and cautions to protect from light and check concentration prior to preparation.*

FDA Label Image

Package Label-principal Display Panel-80 mg Per 8 mL (10 mg/ml) (Container-Carton (1 Vial))

Packaging label for Docetaxel Injection, USP, 80 mg per 8 mL (10 mg/mL) solution for intravenous use. The label indicates it is a multiple-dose vial and includes warnings about cytotoxicity and instructions to check concentration prior to preparation. Distributed by AuroMedics Pharma LLC, the product is made in India. The label includes storage and handling instructions, with a barcode and NDC 55150-379-01.*

FDA Label Image

Package Label-principal Display Panel-160 mg Per 16 mL (10 mg/ml) (Container Label)

Docetaxel Injection, USP 10 mg/mL solution for intravenous use in a 16 mL multiple-dose vial. The label indicates the concentration as 160 mg per 16 mL vial and includes warnings about cytotoxicity and storage instructions. Labeler is Eugia US LLC.*

FDA Label Image

Package Label-principal Display Panel-160 mg Per 16 mL (10 mg/ml) (Container-Carton (1 Vial))

Docetaxel Injection, USP 160 mg per 16 mL (10 mg/mL) multiple-dose vial carton. The label states it is for intravenous use only and ready to add to infusion solution. Contains warnings to check concentration prior to preparation and notes it is a cytotoxic agent. Distributed by Auromedics Pharma LLC, made in India, with storage instructions and ingredient details on the side panel.*

FDA Label Image

Figure 2 (TAX316 Overall Survival K-M Curve)

A survival probability graph comparing two treatment groups labeled TAC and FAC over a period of up to 66 months. The y-axis represents survival probability as a percentage, and the x-axis represents survival time in months. The TAC group is indicated with a solid line, and the FAC group with a dashed line, both showing gradual decline in survival probability over time.*

FDA Label Image

Figure 3 (TAX317 Survival K-M Curves)

A Kaplan-Meier survival curve graph depicting cumulative probability versus survival time in months. Two groups, T75 (solid line) and BSC (dashed line), are compared for overall survival, with a statistically significant difference indicated by a log-rank p value of 0.010.*

FDA Label Image

Figure 4 (TAX320 Survival K-M Curves)

A survival curve graph depicting cumulative probability versus survival time in months for two groups labeled T75 and V/I. The graph includes a log-rank p-value of 0.13 for overall survival comparison, with the x-axis showing survival time up to 21 months and the y-axis showing cumulative probability from 0 to 1.*

FDA Label Image

Figure 5 – Tax327 Survival K-m Curves (Docetaxel Fig5)

A survival curve chart depicting survival probability over survival time in months up to 30 months. Two lines compare survival outcomes between two treatments or groups labeled T75 q3w and M q3w with survival probability on the vertical axis and time on the horizontal axis.*

FDA Label Image

Figure 6 – Gastric Cancer Study (tax325) Time To Progression K-m Curve (Docetaxel Fig6)

A survival probability curve chart comparing two groups labeled TCF and CF over time in months. The y-axis shows probability percentage from 0 to 100%, and the x-axis shows time in months from 0 to 24.*

FDA Label Image

Figure 7 – Gastric Cancer Study (tax325) Survival K-m Curve (Docetaxel Fig7)

A survival curve chart showing survival probability (%) over survival time in months for two groups labeled TCF and CF. The x-axis shows survival time from 0 to 36 months, and the y-axis shows survival probability from 0% to 100%. The chart compares the survival outcomes between the two groups across the study period.*

FDA Label Image

Figure 8 –tax323 Progression-free Survival K-m Curve (Docetaxel Fig8)

A Kaplan-Meier survival curve showing progression-free survival (PFS) probability over time in months. Two treatment groups, TPF (solid line) and PF (dashed line), are compared with PFS probability on the y-axis and progression-free survival time in months on the x-axis. The graph illustrates differences in survival experience between the two groups.*

FDA Label Image

Figure 9 –tax323 Overall Survival K-m Curve (Docetaxel Fig9)

A Kaplan-Meier survival curve chart showing survival probability percentage over survival time in months. The chart compares two groups labeled TPF and PF, with survival probability decreasing over time for both groups, illustrating differences in survival outcomes.*

FDA Label Image

Chemical Structure (Docetaxel Str)

Chemical structure of Docetaxel, showing the detailed molecular arrangement including multiple hydroxyl groups, ester linkages, and aromatic rings characteristic of this chemotherapy agent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.